Last, as already observed for another promising drug for AD, donecopride, acting not only as an AChE inhibitor and a 5-HT4R agonist [55], high doses of agonists could induce the downregulation of 5-HT4 receptors. This evidence concerns the gene HTR4 and Alzheimer disease.